Although undifferentiated human embryonic stem cells (hESCs) are tumorigenic, this
capacity is lost after differentiation, and hESCs are being widely investigated for applications …

Information concerning the development and differentiation of human embryonic stem (hES)
cells in vivo is limited. The present study has focused on the in vivo outcome and …

Little is known about the cell-surface molecules that are related to the undifferentiated and
pluripotent state of human embryonic stem cells (hESCs). Here, we generated a panel of …

Human embryonic stem cells (hESC) have the potential to treat a wide range of diseases.
Currently, the use of existing hESC lines in human clinical applications is limited, as they are …

Human embryonic stem cells (hESCs) are pluripotent stem cells from early embryos, and
their self-renewal capacity depends on the sustained expression of hESC-specific …

The ability of human embryonic stem cells to self-renew and differentiate into all cell types of
the body suggests that they hold great promise for both medical applications and as a …

Hesca-2, a monoclonal antibody (mAb) IgM raised to the human embryonic stem cell (hESC)
line BG-01v, binds with high affinity (nM) to the disaccharide epitope (Galβ1-3GlcNAc) on a …

One of the most pertinent concerns of using differentiated cells derived from human
embryonic stem cells (hESC) is the presence of residual undifferentiated hESC, because …

Embryonic stem (ES) cells have the potential to proliferate indefinitely in culture and can
differentiate into any cell type. The emergence of ES cell lines from human embryos in the …

Recent studies have suggested that human embryonic stem cells (HESC) are immune-
privileged and may thereby circumvent rejection. The expression of immunologically active …